Literature DB >> 15155971

Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects.

Hiroyuki Hashimoto1, Kazuo Kitagawa, Hidetaka Hougaku, Hideki Etani, Masatsugu Hori.   

Abstract

BACKGROUND AND
PURPOSE: Hypertensive outpatients were investigated for C-reactive protein (CRP) and carotid atherosclerosis because the influence of CRP on the progression of subclinical atherosclerosis in hypertensives remains unclear.
METHODS: A total of 124 outpatients (aged 40 to 79 years) in treatment for hypertension were enrolled. They underwent repeated ultrasonographic evaluation of the carotid arteries for 35+/-12 months. Focal intima-media thickening of > or =1.1 mm was defined as plaque, and the plaque number, plaque score, and the sum of all plaque thickness were calculated.
RESULTS: Multivariate linear regression analysis revealed that CRP, pulse pressure, and systolic blood pressure were related to the annual change of plaque number (beta=0.34, 0.27, and 0.30; all P<0.01) and plaque score (beta=0.38, 0.27, and 0.23; P<0.001, P<0.01, and P<0.05, respectively) independently of other risk factors. In 64 patients taking antihypertensive medications with a blood pressure of <140/90 mm Hg, CRP and the pulse pressure were related to the annual change of plaque number (r=0.40 and 0.26; P<0.01 and P<0.05, respectively) and plaque score (r=0.44 and 0.31; P<0.001 and P<0.05, respectively).
CONCLUSIONS: In hypertensive patients being managed by drug therapy or lifestyle modification, CRP is an equivalent or superior independent predictor of the progression of carotid atherosclerosis than the pulse pressure or systolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155971     DOI: 10.1161/01.STR.0000130422.89335.81

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.

Authors:  Tanushree Banerjee; S Joseph Kim; Brad Astor; Tariq Shafi; Josef Coresh; Neil R Powe
Journal:  Am J Kidney Dis       Date:  2014-09-27       Impact factor: 8.860

2.  High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons.

Authors:  R Molino-Lova; C Macchi; A M Gori; R Marcucci; P Polcaro; F Cecchi; F Lauretani; S Bandinelli; R Abbate; E Beghi; J M Guralnik; L Ferrucci
Journal:  Nutr Metab Cardiovasc Dis       Date:  2010-05-31       Impact factor: 4.222

3.  Antihypertensive drugs and inflammation in acute ischemic stroke as a predictor factor of future cardiovascular mortality.

Authors:  Gulcin Benbir; Birsen Ince; Emre Kumral; Zeki Ongen; Hakan Kultursay; Lale Tokgozoglu; Ali Oto; Hasan Tuzun
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

Review 4.  C-reactive protein and hypertension.

Authors:  F G Hage
Journal:  J Hum Hypertens       Date:  2013-11-14       Impact factor: 3.012

5.  Relationships between high-sensitive C-reactive protein and markers of arterial stiffness in hypertensive patients. Differences by sex.

Authors:  Manuel A Gomez-Marcos; Jose I Recio-Rodríguez; Maria C Patino-Alonso; Cristina Agudo-Conde; Leticia Gomez-Sanchez; Emiliano Rodriguez-Sanchez; Marta Gomez-Sanchez; Vicente Martinez-Vizcaino; Luis Garcia-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2012-06-07       Impact factor: 2.298

6.  C-Reactive protein predicts acute myocardial infarction during high-risk noncardiac and vascular surgery.

Authors:  Oscar M Martins; Vicente F Fonseca; Ivan Borges; Vaierio Martins; Vera Lucia Portal; Lucia Campos Pellanda
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  The Relationship between C-Reactive Protein Level and Discharge Outcome in Patients with Acute Ischemic Stroke.

Authors:  He-Hong Geng; Xin-Wang Wang; Rong-Li Fu; Meng-Juan Jing; Ling-Ling Huang; Qing Zhang; Xiao-Xiao Wang; Pei-Xi Wang
Journal:  Int J Environ Res Public Health       Date:  2016-06-27       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.